POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma. It is often associated with disabling polyneuropathy in younger patients. Current therapeutic approaches are frequently inadequate and leave many patients wheelchair-bound with significant deterioration in quality and length of life. We present the case of a young man with progressive disease despite conventional therapeutic approaches. We describe a novel approach to treatment with a boneseeking radiopharmaceutical, samarium-153 ethylene diamine tetramethylene phosphonate ( 153 Sm-EDTMP), followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell reconstitution. This approach resulted in regression of the organomegaly and skin changes and in neurologic improvement both clinically and electrophysiologically. The patient progressed from being wheelchair-bound to independent ambulation. An aggressive approach should be considered in patients with POEMS syndrome in whom standard therapeutic measures fail. Bone Marrow Transplantation (2001) 28, 305-309. Keywords: POEMS syndrome; autologous hematopoietic stem cell transplantation; samarium-153 EDTMP The association between polyneuropathy and monoclonal proteins has been recognized for many years. The acronym POEMS was coined by Bardwick et al 1 to describe a syndrome of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. This syndrome occurs more frequently in Japan, where it is commonly known as Crow-Fukase syndrome.
tension, papilledema (37%), and thrombocytosis. 3 The polyneuropathy associated with POEMS is characterized by mixed sensorimotor changes. Organomegaly usually presents as hepatosplenomegaly and lymphadenopathy, revealing angiofollicular hyperplasia pathologically. Gonadal dysfunction, glucose intolerance, hyperprolactinemia, and hypothyroidism have all been described in the spectrum of endocrinopathies. Hyperpigmentation, plethora, scleroderma-like thickening, hypertrichosis, clubbing, and Raynaud's phenomenon characterize skin changes. 4 Monoclonal gammopathy is present in the majority of patients, with IgG (41%) and IgA (39%) heavy chains predominating, and almost invariably, lambda light chains. POEMS is usually associated with osteosclerotic myeloma, in which patients tend to be younger (median age 51 vs 64 years) and rarely have symptoms of typical myeloma such as bone pain, anemia, hypercalcemia, or renal insufficiency. Their prognosis is better, with an estimated 5-year survival of 60%, 3 and death is almost always related to causes other than multiple myeloma.
The etiology and pathophysiology of POEMS syndrome are currently under intense investigation. It is hypothesized that the syndrome may be mediated by aberrant cytokine or angiogenic factor activity. Elevated serum levels of IL-6 and IL-1␤ have been reported by some investigators, and it has been proposed that levels of IL-6 correlate with disease activity. 5 Soubrier et al 6 have shown that patients with POEMS syndrome have higher levels of TNF-␣ and IL-6 than patients with classic multiple myeloma. Chronically elevated TNF-␣ levels have been associated with inflammatory demyelinating neuropathy, organomegaly affecting liver and spleen, endocrine dysfunction, and skin changes such as hypertrichosis. 7 Vascular endothelial growth factor (VEGF) serum levels have been shown to be markedly elevated in patients with POEMS, 6, 8 and correlate with disease activity. It has been postulated that cytokines or VEGF secreted both from plasma cells and from macrophages in the sclerotic bone lesions may be responsible for inducing the disease manifestations.
Traditional therapeutic approaches have included local radiotherapy, prednisone, melphalan/prednisone, plasmapheresis, and intravenous immunoglobulin. These have been used with variable success, with 57% of patients having some response and 11% having stable disease. 
Case report
A 41-year-old man presented to another institution in April 1996 with progressive neurologic dysfunction. He related the onset of his symptoms to strenuous activity, after which he experienced low back pain. This continued for several days before paresthesias developed in both feet. Over the next couple of weeks, the pain dissipated, but the level of sensory changes progressively ascended, accompanied by weakness in the distal lower extremities and erectile dysfunction. There was no prior history of exposure to neurologic toxins and no family history of neuropathy. Physical examination revealed a sensorimotor neuropathy, and electromyography (EMG) showed changes suggestive of demyelination. The patient underwent five courses of plasma exchange without benefit. Further evaluation revealed a serum monoclonal IgG protein of 0.44 g/dl, and the patient was treated with a 4-day cycle of melphalan and prednisone. After one cycle there was stabilization, but after the second cycle it became clear that the neuropathy had worsened. He went on to develop a profound, predominantly motor neuropathy affecting the lower extremities more than the upper, and presented to our institution in September 1996 for further evaluation. The iliopsoas muscles had only antigravity strength, and with virtually no movement in the lower extremity muscles the patient became wheelchair-dependent. Significant weakness of the hands also developed, making it impossible for him to open packages. Sensory disturbance was noted to the mid-calf and in the fingertips and was associated with burning dysesthesias. Muscle tone was decreased, reflexes were absent in the legs, and EMG revealed dysfunction of large-fiber more than small-fiber sensory modalities. General examination revealed hepatomegaly (liver 4 cm below the right costal margin) and hyperpigmentation of the skin, particularly of the nose and lower extremities.
Laboratory testing included cerebrospinal fluid examination, which revealed a protein level Ͼ200 mg/dl (normal Ͻ35). Endocrine parameters are given in Table 1 . Serum protein electrophoresis and immunofixation results are outlined in Table 2 . Testosterone and vitamin B12 replacement was given. No antibodies were detected with specificity for defined neural antigens. Skeletal survey revealed a single small lytic lesion with a slightly sclerotic rim on the right side of the T10 vertebral body. Computed tomographyguided biopsy revealed a plasmacytoma, and bone marrow examination showed a polyclonal plasma cell staining pattern with 2% plasma cells, a : ratio of 1:1, and a labeling index of 0%. The patient received radiotherapy, 45 Gy, to the T10 vertebral body which dramatically improved the neuropathy. Over the ensuing months, he progressed from being wheelchair-bound to walking with a walker, then with crutches, and subsequently with a cane. The hyperpigmentation was unchanged, and the monoclonal protein remained detectable in the serum.
In 1998, he noted gradual worsening of lower extremity weakness, returning hand weakness, worsening erectile dysfunction, and increased hyperpigmentation. A skeletal survey in June 1998 revealed lytic lesions in the cervical spine, seventh rib, and scapula, with mixed lytic and sclerotic changes in the manubrium and the T10 vertebral body lesion (Figure 1 ). Bone marrow biopsy revealed polyclonal plasma cells. Radiotherapy -45 Gy to the cervical spine, 45 Gy to the left shoulder, 50 Gy to the sternum, and 50 Gy to the right ribs -brought no improvement. Four cycles of therapy with doxorubicin and dexamethasone (without vincristine because of the neuropathy) resulted in a decrease of the M-protein level from 0.5 to 0.25 mg/dl.
In January 1999, a repeat bone survey showed multiple new lesions in the spine, pelvis, and femur. Examination revealed cushingoid facies, diffuse hyperpigmentation, and a liver palpable 8 cm below the right costal margin. Neurologic examination revealed upper and lower extremity weakness with bilateral foot drop and gait ataxia requiring crutches for ambulation and bilateral foot braces. EMG showed distinct worsening of the evoked compound muscle and sensory nerve action potential amplitudes of the upper extremities and no responses in the lower extremities. Overall findings indicated a severe generalized sensorimotor axonal and demyelinating polyradiculoneuropathy.
In view of the severity of the disease and the patient's deteriorating quality of life, he was offered the option of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Hematopoietic progenitor cell collection was performed by using cyclophosphamide, 3 g/m 2 , given as two divided doses of 1.5 g/m 2 on consecutive days, followed by granulocyte-macrophage colony-stimulating factor, 500 g subcutaneously daily for 8 days. A total of 5.84 × 10 6 CD34 + cells/kg were obtained by apheresis over 3 consecutive days. A radioisotope bone scan demonstrated uptake in the neoplastic lesions, and therefore the patient was deemed suitable for 153 Sm-EDTMP therapy (Figure 2 ). He received a total dose of 111 MBq/kg, and follow-up whole body counts were performed to determine when the residual radioactivity was low enough to permit stem cell infusion. Moderate cytopenias developed (hemoglobin 9.6 g/dl, white blood cells 1. by postural hypotension, pruritus, mild glucose intolerance, mucositis requiring central parenteral nutrition, and culturenegative neutropenic fever requiring hospitalization for 6 days. Neutrophil recovery (Ͼ500 × 10 6 /l) occurred on day +13 and platelet recovery (Ͼ50 × 10 9 /l) on day +14. The hepatomegaly resolved during the week after transplantation, and neurologic function gradually improved. Six months after transplantation, he had marked improvement in the strength and mobility of his proximal lower extremities. Bilateral foot drop and mild paresthesias in the hands persisted. EMG showed mild improvement from the pretransplantation EMG (Table 3) . A skeletal survey showed no new lesions. The patient progressively improved in ambulation until he could walk independently. Clinical benefit was still evident at last follow-up 23 months post transplant, with stable neurologic function, resolution of subclinical hypothyroidism, and disappearance of the serum and urine monoclonal protein (Table 2) .
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Discussion
Current therapeutic approaches for POEMS syndrome reportedly provide benefit in 57% of patients and disease stabilization in another 11%. Because it is a rare syndrome, most current chemotherapeutic approaches are based on traditional therapy for multiple myeloma, with omission of neurotoxic agents such as vincristine. Plasma exchange and intravenous gamma globulin are frequently employed for symptomatic polyneuropathy, but are often inadequate. In patients with a solitary plasmacytoma, external-beam radiation therapy with or without surgical excision may lead to regression of the neuropathy for years. This observation supports the hypothesis that POEMS is a paraneoplastic phenomenon mediated by soluble factors produced by abnormal plasma cells. We postulate that systemic approaches with chemotherapeutic or radiopharmaceutical agents are required to achieve remission when plasma cells
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Figure 2
Radioisotope bone scan demonstrating uptake and therefore making the patient a suitable candidate for samarium-153 EDTMP therapy.
Table 3
Electromyographic findings from before (1/99) and 6 months after transplantation (9/99) are not confined to an isolated area, and high-dose therapy with stem cell rescue may be more effective than traditional doses of chemotherapy at achieving this goal. The radiopharmaceutical 153 Sm-EDTMP is a potent short-range ␤ particle-emitting radioisotope ( 153 Sm) conjugated to a bone-seeking chelate (EDTMP). The 153 Sm-EDTMP becomes deposited on the surface of trabecular and cortical bone, and less than 2% of its activity is retained in non-osseous tissue 3 h after administration, 9 with complete urinary excretion 6 h after injection. 10 It has a relatively short half-life (46.7 h) and has been studied extensively for the treatment of painful osseous metastasis.
It has been found effective in this setting, with temporary myelosuppression as the main toxicity. Turner and colleagues 12 reported results with 153 Sm-EDTMP and melphalan in murine myeloma. They found that median survival after treatment with nonmyeloablative doses of 153 Sm-EDTMP (29 days) and melphalan (31 days) was significantly prolonged, compared with untreated mice (23 days). Syngeneic bone marrow transplantation after myeloablative doses of 153 Sm-EDTMP with melphalan was even more effective (42 days). There was no evidence of radiotoxicity in nonhematopoietic organs. This approach permits specific bone marrow ablation with minimal nonhematopoietic toxicity. It may be suitable for patients who cannot be treated with standard total-body irradiation because of extensive prior external-beam radiation therapy.
Given the severity of the disease in our patient and the fact that he no longer responded to standard therapy, a novel therapeutic approach was required. There is preliminary evidence to suggest that autologous hematopoietic progenitor cell transplantation may benefit patients with other low-grade dysproteinemias. [13] [14] [15] Many investigators have shown that high-dose melphalan followed by hematopoietic stem cell reconstitution results in reversal of amyloid deposition syndromes in two-thirds of patients surviving at 1 year. 16 This therapeutic approach was offered to our patient because it has been shown to have benefit in multiple myeloma, with a mortality risk of less than 2%. 17, 18 He has had a favorable response, with dramatic regression of the organomegaly and skin changes and a significant decrease in the monoclonal protein. The neuropathy continues to improve clinically and by electromyography. An aggressive approach should be considered in patients with POEMS syndrome who fail to respond to standard therapeutic measures. This is likely to provide maximal benefit if it is begun before permanent loss of neurologic function.
